We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Angle plc (AGL) Ordinary 10p

Sell:97.00p Buy:98.00p 0 Change: 0.50p (0.52%)
Market closed Prices as at close on 1 July 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:97.00p
Buy:98.00p
Change: 0.50p (0.52%)
Market closed Prices as at close on 1 July 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:97.00p
Buy:98.00p
Change: 0.50p (0.52%)
Market closed Prices as at close on 1 July 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ANGLE plc is a United Kingdom-based specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

Contact details

Address:
The Surrey Research Park, 10 Nugent Road
GUILDFORD
GU2 7AF
United Kingdom
Telephone:
+44 (01483) 343434
Website:
https://www.angleplc.com/

Important dates

Future events
There are no future events available.
Past events
AGM 29 June 2022 29/06/22
Final results 28 April 2022 28/04/22
Interim results 30 September 2021 30/09/21

General stock information

EPIC:
AGL
ISIN:
GB0034330679
Market cap:
£229.41 million
Shares in issue:
235.29 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Andrew Newland
    Chief Executive, Executive Director
  • Ian Griffiths
    Finance Director, Company Secretary, Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.